Clik here to view.
OPK, ROX, LTS , Dr. Phillip Frost Update
Castle Brand holders cheer the Frost Upsurge We track three major positions for Jack A. Bass Managed Accounts and after the ROX haircut we are happy to see our profits regrowing at a faster trading...
View ArticleClik here to view.
OPKO Health Oppenheimer Coverage / Rating Outperform
Investment analysts at Oppenheimer assumed coverage on shares of Opko Health (NYSE:OPK) in a note issued to investors on Thursday, Analyst Ratings Network.com reports. The firm set an “outperform”...
View ArticleClik here to view.
Trading Alert : Insider Buying and Soros pushing OPK Higher
According to GuruFocus Insider Data, these are the largest CEO buys during the past week. The overall trend of CEOs is illustrated in the chart below: Opko Health Inc. (OPK): CEO and Chairman, 10%...
View ArticleClik here to view.
Motley Fool Damns OPKO with Faint Praise
Opko Health (NYSE: OPK) – Friday March 28 Finally, we have hybrid diagnostic and pharmaceutical product developer Opko Health, which offers a great degree of promise thanks to a pipeline that spans a...
View ArticleClik here to view.
OPKO Health Gains With News Release
OPKO HEALTH INC(OPK:NYSE, US) 9.25USD0.29(3.24%)Volume: Average As of 31 Mar 2014 at 12:04 PM EDT. QUOTE DETAILS Open 9.03 P/E Ratio (TTM) – Last Bid/Size 9.25 / 11 EPS (TTM) -0.33 Last Ask/Size...
View ArticleClik here to view.
OPKO Health NR – Aquisition
OPKO Acquires Next Generation Dry Powder Inhaler to Treat Respiratory Disorders OPKO HEALTH INC(OPK:NYSE, US) 8.20USD0.13(-1.56%)Volume: Average As of 17 Apr 2014 at 11:53 AM EDT. kip Navigation...
View ArticleClik here to view.
Reversed Our Positions on Dr. Phillip Frost
Sold out of ROX at an average of $ 1.15 Is America going to stop drinking ? CASTLE BRANDS INC(ROX:NYSE MKT LLC, US) 0.8599USD0.0831(-8.81%)Volume: Above Average As of 30 Apr 2014 at 12:53 PM EDT....
View ArticleClik here to view.
Opko Health’s New Era Begins : Motley Fool
Following massive investments over the past two years that have swelled spending on research and development and included a slate of acquisitions, Opko Health (NYSE:OPK) could soon be on its way to...
View ArticleClik here to view.
Opko Health : One To Watch In 2016 – Motley Fool
What: After reporting an upside surprise in third-quarter earnings and the mid-month launch of its first royalty-producing drug by partner Tesaro (NASDAQ:TSRO), shares in Opko Health (NYSE:OPK)...
View Article
